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Background. It is well acknowledged that glucocorticoid (GC) replacement can unmask diabetes insipidus (DI) in subjects with
hypopituitarism. Objective. To increase the awareness and monitoring for transient and symptomatic DI in children with partial
hypopituitarism during periods in which increased GC needs are required. Methods/Case. A 2-month-old female infant with
septo-optic dysplasia (SOD; on thyroid and maintenance GC replacement therapy at 8 mg/m2/day) developed transient DI during
2 separate episodes of stress (one hypothermia, one febrile) when stress dosing of GC (25 mg/m2/day) was instituted. Conclusion.
Children not diagnosed with DI during initial evaluation for hypopituitarism may benefit from rescreening of serum sodium levels
during acute periods of stress that demand “stress” GC dosing. This will permit treatment and/or increased vigilance for ensuing
permanent DI.
1. Background
Septo-optic dysplasia (SOD) is a malformation syndrome in
which at least 50% of children have associated hypopitu-
itarism [1, 2]. This condition includes agenesis of the septum
pellucidum, hypoplasia, or aplasia of the optic nerves and
chiasm that results in various degrees of visual impairment
and abnormality of the hypothalamus causing secondary
hypopituitarism [3]. Diabetes insipidus (DI) is a condition
characterized by excretion of large volumes of dilute urine
secondary to either a deficiency in the production/release of
the hormone arginine vasopressin (AVP) that is synthesized
in the hypothalamus and transported and stored in the
posterior pituitary for release in response to a rise in
plasma concentrations of osmotically active substances or an
impaired response or resistance to AVP at the level of the
kidney (nephrogenic DI, 4). The most common form of DI is
due to a primary deficiency of AVP. Central DI due to midline
brain abnormalities may also be accompanied by a defective
thirst mechanism [4].
Here we present an infant in whom DI was not present
during maintenance GC replacement but was unveiled
during two episodes in which “triple stress GC dosing” was
accompanied by temporary DI.
2. Methods/Case
Patient is a 2-month-old female with SOD diagnosed in the
newborn period secondary to hypoglycemia and hypotonia.
SOD was confirmed by both MRI and ophthalmologic
exam. Hypopituitarism manifested with central hypothy-
roidism and hypoadrenalism such that her medications at
presentation included thyroid supplementation (37.5 mcg or
10 mcg/kg/day) and hydrocortisone (8 mg/m2/day).
On day of life no. 70, she presented to the ED at the OSH
with apnea and lethargy (which responded to stimulation),
dehydration, and hypothermia (temperature 33.78◦C). She
underwent a septic workup, including urine and blood
cultures, that were negative. Of note, her initial serum
sodium (Na) was 153 mmol/L (range 135–145 mmol/L). She
received a dose of ceftriaxone and an initial stress dose GC
of 25 mg (100 mg/m2) at the OSH and then transferred to
our PICU. Repeat serum Na was then 155 mmol/L, and she
was treated with a normal saline intravenous (IV) fluid bolus
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Figure 1: Association of serum Na levels with (1) GC dosing and then (2) DDAVP administration over time. The eﬀect of stress HC dosing
and DDAVP on serum Na levels in a patient with SOD. As shown on the y axis, serum Na (levels mmol/L, ) rise on each occasion in which
HC dosing is increased over maintenance dosing (∗), consistent with an unmasking of DI in child with partial hypopituitarism over time
(x axis). Note that during a prolonged afebrile period and maintenance dosing, serum Na levels remained in the normal range (pink bar).
In this patient, the transient DI during febrile episodes and GC stress dosing was then followed by progression to permanent DI with serum
Na of 163 mmol/L, USG of 1.005, and an AVP level of <0.6 pg/mL, and patient was then maintained on DDAVP. Please note that the DDAVP
doses were intranasal (IN) preparations given orally, so the eﬀective DDAVP dose is 1/10 of the listed dose.
and then maintained on D5.5 NS at maintenance for a 12-
hour period. Her Na rose to 160, and she was given DDAVP
(10 mcg of intranasal solution given orally; eﬀective dose of
1 mcg). During this time she continued GC stress dosing of
2.3 mg hydrocortisone every 8 hours (at 25 mg/m2/day; see
Figure 1).
Approximately 10 hours later, while on oral feeds and
no supplemental IVF, her Na level dropped to 147 (rate
of 1.2 mmol/hour). Oral feeds continued without DDAVP
and, after 17 hours, her Na level again rose to 157 mmol/L.
A second lower dose of DDAVP (eﬀective dose of only
0.5 mcg) was then given as she appeared dehydrated and
was tachycardic. Accurate urine output was not obtained as
patient had not been catheterized. Surprisingly, this second
dose resulted in an acute drop in her Na to 130 mmol/L
over twelve hours (2.25 mmol/hour) and was accompanied
by seizure activity. The patient was on oral feeds by this
time, with IVF at 2 mL/hr to maintain IV patency. Her
serum sodium levels normalized to 136–142 mmol/L over the
following 18-hour period with fluid restriction.
Once normothermic, she was returned to her mainte-
nance GC dose, and, of note, no subsequent doses of DDAVP
were required during this 6-day period. At this time, a
modified water deprivation test was performed and, at time
of 15 hours, the patient’s serum Na remained normal at 141
with a USG of 1.014, arguing against fulminant DI.
A subsequent febrile episode (temp 38.6◦C) led to rein-
stitution of stress GC dosing (at 47 mg/m2/day) with repeat
blood and urine cultures being negative. Again, her serum
Na increased to a peak of 163 mmol/L and was accompanied
by a USG of 1.005, a weight loss of 1.72 kg as well as an AVP
level that was notably undetectable at <0.6 pg/mL (Mayo
Clinic, Rochester, MN), supporting the diagnosis of another
episode of “unmasking” of DI. Consequently, DDAVP was re-
instituted, albeit at a markedly conservative dose of 2.50 mcg
of IN preparations given orally (eﬀective dose of 0.25 mcg)
that successfully maintained her Na levels within a range of
145–155 mmol/L. Interestingly, she has been maintained on
this dose since that time, given that her “transient” episodes
seen during the increased GC exposure ultimately progressed
to permanent, although likely “partial,” DI.
3. Results/Conclusions
Although the “unmasking of DI” upon institution of GC
replacement in children with pituitary insuﬃciency is well
recognized, the mechanism of the sequelae is less well
delineated. Both a GC-induced decrease in AVP release
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as well as inhibition of action at the level of the kidney
has both been reported [5]. For example, Yamada et al.
[6] demonstrated that corticotropin releasing hormone
(CRH) administration augmented plasma arginine vaso-
pressin (AVP) in response to an osmotic stimulus. The
authors also reported that cortisol administration to patients
with hypopituitarism decreased plasma AVP response to the
osmotic stimulus [6]. Consequently, the authors deduced
that the eﬀect of cortisol was due to a central suppression
of the AVP response to an osmotic stimulus. Furthermore,
given that basal plasma renin activity, plasma aldosterone,
plasma osmolality, hematocrit, body weight, mean blood
pressure, and heart rate were similar in subjects with and
without cortisol administration, the authors proposed that
the eﬀect of cortisol may be related to suppression of AVP
release in response to osmotic stimuli. Furthermore, when
the authors then pretreated the patients with DI with 20 mg
of hydrocortisone, they found no significant change in the
basal AVP levels; however, the maximal AVP response to
an osmotic stimulus was significantly attenuated, thereby
suggesting that CRH suppression by GCs was via inhibition
of the AVP release [6]. In contrast, Linas et al. [7] measured
total urine volume and USG in adrenalectomized rats and
found that GC deficiency impairs renal water excretion.
Moreover, Linas and colleagues demonstrated that GC-
treated rats had a significantly higher urine flow (GFR)
[7].
To date, no cases have been reported in which DI was
induced only when greater than maintenance dosing of
GCs were given. In our patient, DI was unmasked initially
during a presumed viral illness only during episodes where
stress dose GCs were required, suggesting a mild/partial
DI, especially given the markedly low dose of DDAVP
required to control her DI despite unmeasurable endogenous
AVP levels during period of elevated serum Na levels and
low USG. Interestingly, after the continued need for stress
GC dosing, permanent, although likely still partial, DI
evolved with low dosing requirement, suggesting that we
may have unmasked the progression of natural development
to DI that was occurring but was brought to medical
attention during her periods of increased GC require-
ments.
This case supports, therefore, that, in children who have
not been diagnosed with DI during their initial evaluation
for hypopituitarism (e.g., SOD), rescreening of serum Na
levels (along with parallel USG or osm along with body
weight monitoring) during episodes of acute stress and
concomitant increased GC dosing may, indeed, be clinically
relevant by unveiling a partial/complete DI. Such vigilance
could then obviate symptomatic DI, particularly in a young
infant or in a child whose thirst mechanism may be either
diﬃcult to assess (since feeds are still formula) or may
be impaired. It is also important to note, since DI could
still be partial as it was in our patient, that the dosing of
DDAVP is done conservatively and only when the patient
has clinical signs of DI (e.g., hypernatremia accompanied by
dehydration and/or weight loss). Finally, the DI should also
be viewed as transient/episodic until permanent DI has been
declared.
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